Cover Image
市場調查報告書

糖蛋白質41 (gp41) :開發中產品分析

Glycoprotein 41 (gp41) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363121
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
糖蛋白質41 (gp41) :開發中產品分析 Glycoprotein 41 (gp41) - Pipeline Review, H1 2018
出版日期: 2018年04月10日 內容資訊: 英文 67 Pages
簡介

本報告提供糖蛋白質41 (gp41)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症
  • 開發中的產品:各企業
  • 開發中的產品:各大學/研究機關

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Amunix Operating Inc
  • Frontier Biotechnologies Inc
  • InnaVirVax SA
  • Longevity Biotech Inc
  • Mymetics Corp
  • Navigen Inc
  • Osel Inc
  • Pharis Biotec GmbH

藥物簡介

暫停的計劃

開發中止的計劃

產品開發里程碑

  • 最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1401TDB

Summary:

According to the recently published report 'Glycoprotein 41 (gp41) - Pipeline Review, H1 2018'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

The report 'Glycoprotein 41 (gp41) - Pipeline Review, H1 2018' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 6 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
  • The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glycoprotein 41 (gp41) - Overview
    • Glycoprotein 41 (gp41) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Glycoprotein 41 (gp41) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development
    • Amunix Operating Inc
    • Frontier Biotechnologies Inc
    • InnaVirVax SA
    • Longevity Biotech Inc
    • Mymetics Corp
    • Navigen Inc
    • Osel Inc
    • Pharis Biotec GmbH
    • Sanofi Pasteur SA
  • Glycoprotein 41 (gp41) - Drug Profiles
    • CPT-31 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DS-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enfuvirtide-XTEN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FB-006M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIV-1 vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBT-5001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MYMV-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MYMV-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STOP-3S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhbit GP41 for HIV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAC-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAC-3S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VCP-2438 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIR-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glycoprotein 41 (gp41) - Dormant Products
  • Glycoprotein 41 (gp41) - Discontinued Products
  • Glycoprotein 41 (gp41) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 18, 2017: Navigen Awarded $4.9MM to Advance its HIV Entry Inhibitor CPT31
      • Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines
      • Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science
      • Nov 28, 2016: First new HIV vaccine efficacy study in seven years has begun
      • Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting
      • Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development
      • Aug 24, 2016: Navigen Awarded $500,000 Grant to Support Depot Formulation of its HIV Drug Candidate
      • Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial
      • May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US
      • May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa
      • Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed
      • Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic
      • Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine
      • Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics
      • Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Amunix Operating Inc, H1 2018
  • Pipeline by Frontier Biotechnologies Inc, H1 2018
  • Pipeline by InnaVirVax SA, H1 2018
  • Pipeline by Longevity Biotech Inc, H1 2018
  • Pipeline by Mymetics Corp, H1 2018
  • Pipeline by Navigen Inc, H1 2018
  • Pipeline by Osel Inc, H1 2018
  • Pipeline by Pharis Biotec GmbH, H1 2018
  • Pipeline by Sanofi Pasteur SA, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top